Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
polyhexamethylene biguanide
- Development stage
- Unknown
- Lead developer
- National Institute of Allergy and Infectious Diseases
- Modality
- Peptides
- Administration
- Topical
01
Overview
Polyhexamethylene biguanide (PHMB), also known as polyhexanide, is a cationic polymer and broad-spectrum antiseptic widely used in wound care and oral hygiene. It has demonstrated impressive anti-leishmanial activity in vitro and in vivo against multiple species of *Leishmania*. PHMB acts primarily by entering cells and binding to nucleic acids, leading to cell death, rather than solely disrupting the microbial membrane. It is currently being investigated for the treatment of cutaneous leishmaniasis.
- Other names
- polyhexanide
02
Targets
DNA
Beyond the preview
Go deeper on polyhexamethylene biguanide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on polyhexamethylene biguanide.